Safety and efficacy of tolebrutinib, an oral brain-penetrant BTK inhibitor, in relapsing multiple sclerosis: a phase 2b, randomised, double-blind, placebo-controlled trialDaniel S. Reich, Sibyl Wray, Michaela Týblová et al.|The Lancet Neurology|2021Cited by 192
Plasma exchange for acute attacks of CNS demyelinationSara Llufriú, Albert Saiz, Joaquim Castilló et al.|Neurology|2009Cited by 190
Neurofilament light chain and oligoclonal bands are prognostic biomarkers in radiologically isolated syndromeClara Matute‐Blanch, Manuel Comabella, Luisa María Villar et al.|Brain|2018Cited by 161
Neuromyelitis optica spectrum disordersMaría Sepúlveda, Inmaculada Puertas, Thaís Armangué et al.|Neurology Neuroimmunology & Neuroinflammation|2016Cited by 153
Grey and white matter volume changes in early primary progressive multiple sclerosis: a longitudinal studyJaume Sastre‐Garriga, Alan J. Thompson, Gordon Ingle et al.|Brain|2005Cited by 145